Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC

Evangeline Samuel, Gabrielle Lie, Adithya Balasubramanian, Alison Hiong, Yeojeong So, Mark Voskoboynik, Maggie Moore, Mark Shackleton, Andrew Haydon, Tom John, Paul L.R. Mitchell, Ben Markman, Peter Briggs, Sagun Parakh

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)


There are limited data examining the impact of radiotherapy (RT) on the efficacy of checkpoint inhibitors in patients with metastatic non–small-cell lung cancer (NSCLC). In this study, we aimed to evaluate the impact of RT on the efficacy and toxicity of anti-programmed death 1 treatment in patients with metastatic NSCLC treated in a nonclinical trial setting. Our findings show that in patients with metastatic NSCLC, the addition of RT to immune checkpoint inhibitors was not associated with increased toxicity or improved survival.

Original languageEnglish
Number of pages6
JournalClinical Lung Cancer
Publication statusAccepted/In press - 10 Jun 2020


  • Abscopal effect
  • anti- PD-1 inhibitors
  • Immune related adverse events
  • Immunotherapy
  • Metastatic NSCLC

Cite this